Navigation Links
XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Date:9/25/2007

VALLEY COTTAGE, New York, September 25 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announces today that its Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") was postponed for one week in accordance with its articles of association due to the absence of a quorum. The postponed AGM and EGM will take place at the Company, Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100 at 4:00 pm and 4:30pm, respectively on October 2, 2007.

Any proxy votes received at any time up to 48 hours prior to the postponed AGM and EGM will be included in the total votes counted for the AGM and EGM. Those shareholders who have a valid "proof of ownership" in Israel or a letter of representation from Computershare, the Company's registrars, and attend the meeting in person will also be permitted to vote.

As a result of postponing the EGM, the Company anticipates that the time and date for the cancellation of the listing of its Ordinary Shares from the Official List of the United Kingdom Listing Authority, being not less than 20 business days from the date of the EGM as required by the United Kingdom Listing Rules, is now 8:00 am (London Time) on October 31, 2007.

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain. XTL is also developing several novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur

Chief Executive Officer

Tel: +1-845-267-0707, ext. 225


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. 42 days until the 2006 Olympics of Biotechnology in Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Ann Arbor, MI (PRWEB) , ... February 16, 2017 , ... ... between 5:00-7:00 p.m. The event will be held at Avomeen Analytical Services (4840 ... hosted by a MichBio member organization. They provide an opportunity to interact with peers, ...
(Date:2/16/2017)... PARK, Calif. and GREENWICH, ... Capital, a private investment firm focused on venture ... announced the promotion of Josh Richardson , ... focuses on investments in biotechnology companies.  He is ... has played important roles in Longitude,s investments in ...
(Date:2/16/2017)... CALABASAS, Calif. , Feb. 16, 2017 /PRNewswire/ ... on developing groundbreaking therapies to treat severe neurological ... in children treated with AGT-181, the company,s investigational ... syndrome (also known as mucopolysaccharidosis type I, or ... Phase 2 proof-of-concept (POC) study, presented today at ...
(Date:2/16/2017)... ANGELES , Feb. 16, 2017   ... ), a clinical-stage biotechnology company developing first-in-class biological ... announced that it has elected to terminate its ... natriuretic peptide receptor agonists, including Cenderitide. ... strategic move as we prioritize our efforts to ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
Breaking Biology News(10 mins):